Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scios Natrecor

Executive Summary

Nesiritide is not approvable for treatment of acute episodes of congestive heart failure, FDA tells company April 27. "The agency determined that further study is needed to define the consequences of the pharmacodynamic profile, specifically as it relates to the onset of effect and the recovery from hypotension if it occurs," the company said. Scios noted that "FDA acknowledged that Natrecor reduced pulmonary capillary wedge pressure, increased cardiac output, and produced some evidence of symptomatic benefit." The product was recommended for approval in treating chronic decompensated CHF by FDA's Cardio-Renal Drugs Advisory Committee in January ("The Pink Sheet" Feb. 1, p. 5)
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS034106

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel